Formosa Laboratories, Inc. Stock

Equities

4746

TW0004746003

Pharmaceuticals

End-of-day quote Taiwan S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
106.5 TWD +0.95% Intraday chart for Formosa Laboratories, Inc. -7.39% +4.41%
Sales 2024 * 5.09B 157M Sales 2025 * 5.77B 178M Capitalization 12.81B 395M
Net income 2024 * 706M 21.78M Net income 2025 * - EV / Sales 2024 * 2.93 x
Net Debt 2024 * 2.08B 64.33M Net Debt 2025 * 1.97B 60.84M EV / Sales 2025 * 2.56 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
2.79%
Yield 2025 *
4.96%
Free-Float 83.74%
More Fundamentals * Assessed data
Dynamic Chart
Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Formosa Laboratories, Inc. Approves Dividend Distribution for Full Year Ended December 31, 2023 CI
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance MT
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals MT
Formosa Laboratories, Inc. Announces Change of Members of the Sustainable Development Committee CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Formosa Laboratories, Inc. Appoints Lin Chien-Fei as Chief Information Security Officer CI
Formosa Laboratories, Inc. Announces Cash Dividend, Payable on September 22, 2023 CI
Formosa Laboratories, Inc. Announces Appointment of New Members of Audit Committee CI
Formosa Laboratories, Inc. Approves Independent Directors Elections CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day+0.95%
1 week-7.39%
Current month-0.93%
1 month+5.97%
3 months-6.99%
6 months+35.15%
Current year+4.41%
More quotes
1 week
104.50
Extreme 104.5
114.50
1 month
98.60
Extreme 98.6
121.00
Current year
96.80
Extreme 96.8
121.00
1 year
76.70
Extreme 76.7
121.00
3 years
44.20
Extreme 44.2
121.00
5 years
29.75
Extreme 29.75
121.00
10 years
29.75
Extreme 29.75
121.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 95-12-28
Director of Finance/CFO - 03-04-13
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 86 10-05-10
Chief Executive Officer - 95-12-28
Director/Board Member - 06-08-09
More insiders
Date Price Change Volume
24-04-18 106.5 +0.95% 1,830,839
24-04-17 105.5 -1.86% 3,236,685
24-04-16 107.5 -2.27% 2,585,328
24-04-15 110 -2.65% 2,267,184
24-04-12 113 -1.74% 3,258,291

End-of-day quote Taiwan S.E., April 17, 2024

More quotes
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
106.5 TWD
Average target price
137.5 TWD
Spread / Average Target
+29.11%
Consensus